The trial was conducted across over 120 centres in 12 nations, including Canada, and regions across Asia and Europe.

AstraZeneca (LSE:AZN) recently released positive results from its POTOMAC Phase III trial involving IMFINZI, reflecting ...

Shares of AstraZeneca PLC (AZN) traded 1% higher in pre-market on Friday after the company reported positive results from its ...

AstraZeneca's run of positive trial results with its cancer therapies has continued with a win for its immunotherapy Imfinzi ...

Earlier this year, AstraZeneca took Imfinzi to new heights in muscle-invasive bladder cancer (MIBC) with an FDA nod that made it the first immunotherapy cleared to treat patients both before and ...

In the POTOMAC study, one year of treatment with Imfinzi (durvalumab) plus standard-of-care BCG induction and maintenance ...

The Food and Drug Administration (FDA) has approved Imfinzi ® (durvalumab), in combination with gemcitabine and cisplatin as neoadjuvant treatment, followed by single agent Imfinzi as adjuvant ...

The FDA has recently approved AstraZeneca’s Imfinzi (durvalumab) for perioperative use in cisplatin-eligible muscle-invasive bladder cancer (MIBC), based on the Phase III NIAGARA trial. With its ...

Imfinzi plus BCG induction and maintenance therapy showed a statistically and clinically meaningful improvement in DFS for ...

(RTTNews) - AstraZeneca Plc. (AZN, AZN.L) announced that results from the POTOMAC Phase III trial showed that one year of treatment with its Imfinzi (durvalumab), combined with standard Bacillus ...

Following the recent discontinuations of assets in Alzheimer’s and migraine, AstraZeneca is stepping away from neuro ...

AstraZeneca expects only limited impact from potential U.S. tariffs on pharmaceutical imports, the drugmaker said on Tuesday, ...